REALITEC Subgroup Analysis: A Multi-Country Observational Retrospective Study of Teclistamab in Patients With Relapsed/Refractory **Multiple Myeloma Outside** of Clinical Trials

Rakesh Popat¹, K Martin Kortüm², Katarina Uttervall³, Sarah Leeth Farmer⁴, Michele Cavo⁵, Bhuvan Kishore⁶, Caroline Jacquet⁷, Maria Casanova⁸, Markus Hansson⁹, Katia Weisel¹⁰, Hila Magen¹¹, Carmine Liberatore¹², Charlotte Toftmann Hansen¹³ Moshe Gatt¹⁴, Tamir Shragai¹⁵, Matteo Claudio Da Vià¹⁶, Teresa De Soto Alvarez¹⁷, Mathew Streetly¹⁸, Marc-Steffen Raab¹⁹, Salomon Manier²⁰, Jesper Aegesen²¹, Rana Takchi²², Peter Hu²³, Diptendu Santra²⁴, Vadim Strulev²⁵, Claire Albrecht²⁶, Eva Rubio-Azpeitia²⁷, Aurore Perrot²⁸

*UniversityCdiege London Hospitals NHSFoundation Tust, London, UK *UniversityHospital & Würzburg, Würzburg, Germany; *Kardinska UniversityHospital, Stockholm, Sweden,*Vejle Hospital *Dapattment of Meddaf and Sungial Sterece, Bologna UniversitySchool of Medicine, Bologna, Italy, "UniversityHospital: Biomingham, NHSFoundation Tust, Binningham, UK, "Service d'hématole vonninum-Ak-Nexnor, France *Hosail do Sada el SJ. Muthola, Sanix: "Sanikersite Nexnorma (Stadoug University Hospital Schligersite) Sanikersite, Biomingham, UK, "Service d'hématole vonninum-Ak-Nexnor, France *Hosail do Sada el SJ. Muthola, Sanix: "Sanikersite Nacional Von Stadiy Sanikersite University Hospital, Cichenturg) sweder, State University Hospital, Schligersite, Sanikersite, Alexnorma University Hospital, Sanikersite, Sanikersit ligrenska Academy Goteborg University & Sahigrenska University n Sheba Medical Center, Ramat-Gan, Israel; Sackler Faculty of M Hadassah Medical Center, Faculty of Medicine, Hebrew Univer S Fondazione Ca`Granda Ospadale Maggiore Polidinico, Milan, v Hostital Heideberg and Olnical Coxperation Unit Molecular He ences. Tel Av

Key Takeaway

REALITEC demonstrates comparable outcomes to MajesTEC-1 in heavily pretreated patients treated outside of clinical trials, with no differences in effectiveness in subgroups who have historically poorer outcomes, confirming teclistamab as a standard of care in a broad patient population

Conclusions



REALITEC has demonstrated good effectiveness and manageable toxicity in a hard-to-treat RRMM patient population, with better outcomes in patients who achieved deep response (≥VGPR), those eligible for MajesTEC-1, and those without prior exposure to BCMA ADCs

Teclistamab is effective in patients with prior BCMA, with ORR 52.6% and ≥VGPR 47.4%, similar to MajesTEC-1 cohort C. However, prior exposure to BCMA ADCs seemed to adversely affect PFS and OS in our cohort. More data on sequencing BCMA therapies is needed to confirm this finding

Subsequent cohorts of REALITEC, REALITEC 2 and 3 will help inform optimal patient management, sequencing, and outcomes in the real world



https://www.congresshub.com/EHA2025/Oncology/Teclistamab Popat-REALITEC

The QR code is intended to provide scientific information for individual reference, and the information should not be allered or reproduced in

Introduction

- Teclistamab is the first approved bispecific monoclonal antibody targeting B-cell maturation antigen (BCMA) and CD3 for the treatment of patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)1-3
- With a median follow-up of 30.4 months, the pivotal phase 1/2 trial MajesTEC-1 (N=165) showed deep and durable responses with teclistamab in patients without prior BCMA-targeted treatment^{1,4}
- Overall response rate (ORR) was 63% with a complete response or better (≥CR) rate of 46.1% and a very good partial response or better (≥VGPR) rate of 59 4%4
- In the subgroup analysis of MajesTEC-12, patients who were penta-refractory, had high risk cytogenetics, or were aged ≥75 years had similar response rates and compared with the overall study population
- Patients in earlier lines of therapy (<3 prior lines) had numerically higher median progression-free survival (PFS) and overall survival (OS) compared with the study population⁵

Results

Patient disposition

- Overall, 113 patients were included in the study; 100 from preapproval access programs and 13 treated with commercial teclistamab
- Patient baseline characteristics are shown in the Table

Table: Baseline demographics and disease characteristics

Characteristic	N=113'
Age, years, median (range)	66 (43–86)
<65 years, n (%)	47 (41.6)
≥65 to <75 years, n (%)	49 (43.4)
≥75 years, n (%)	17 (15.0)
Male, n (%)	57 (50.4)
ECOG PS ≥1, n (%)	27/49 (55.1)
ISS stage II or III, n (%)	62 (54.8)
High-risk cytogenetics, ^b n (%)	32/62 (51.6)
Extramedullary plasmacytoma, n (%)	9/59 (15.3)
Patients ineligible for MajesTEC-1, n (%)	78 (69.0)
Years since diagnosis, median (range)	6.88 (0.7–24.2)
Previous lines of therapy, median (range)	6 (2–12)
Triple-class exposed, n (%)	113 (100)
Penta-class exposed, n (%)	100 (88.5)
Triple-refractory, n (%)	89 (78.8)
Penta-refractory, n (%)	50 (44.2)
Refractory to the last line of the rapy, n (%)	86(76.1)
Autologous SCT, n (%)	86(76.1)
Patients receiving prior BCMA, c n (%)	38 (33.6)
Number of the rapies	43
CAR-T	10
ADC	32
BsAbs	1

*Data available added as denominators if some were missing and not available in the clinical chart for the whole cohort. ¹High risk defined as having presence of (14:14), (14:16), del17p13, and amp1q21. ¹38 patients received 43 prior BCMA-directed herapies. ADC, antibody-drug conjugate; BAB, bispecific antibody; CAR, chimeric antigen receptor; ECOG PS, Eastern Cooperative Oncology Group performance status; ISS, International Staging System; SCT, stem cell transplant.

- The 38 patients with prior exposure to BCMA-targeted therapy had a longer median time since diagnosis (9.3 years [range, 0.7-24.2]) vs
- therapy (range, 3-12) vs 5 PL (range, 2-12) in the non-BCMAexposed patients, with most having ≥5 PL (89.5% vs 60%)

Response rates


- With a median follow-up of 20.7 months, ORR for the whole cohort was 60.2% with a \geq VGPR rate of 52.2%
- Response rates from subgroups were consistent with the overall patient population and across them, with ORRs ranging from 58-68.8% and ≥VGPR rates from 47.1–64.7% (Figure 2)

1 Usmani SZ et al. / Clin Orcd 2023;41(16 suppl):8034.2 TECVAYI @ (tedistamah-cow) Prescribion information Horsham PA: Johnson & Johnson: 2024.3 TECVAYI @ (tedistamah). Summary of product characteristics 7. Kortüm M, et al. Presented at EMN; April 10–12, 2025; Athens, Greece.


- MajesTEC-1 cohort C also demonstrated promising results in patients exposed to prior BCMA-targeting treatments, with 52.5% ORR, 47.5% ≥VGPR, and 30% ≥CR rates³
- Initial effectiveness and safety data from REALITEC have been previously reported.^{6,7} Here, we report the subgroup analysis of the REALITEC study, a retrospective observational study of patients receiving teclistamab outside of clinical trials

Methods

- REALITEC is a retrospective, international, noninterventional study that aimed to describe the management and outcomes of patients treated with teclistamab outside of clinical trials
- Informed consent was obtained for all patients
- Data were collected from patient medical records, including demographics, disease characteristics, prior therapies, effectiveness, and safety




- a ≥VGPR rate of 47.4% (Figure 3)



Survival outcomes

- In the overall cohort, median DOR was 20.3 (14.8-not evaluable [NE]) 26.2 (16.5-NE) months
- Patients achieving ≥VGPR had a trend towards longer median DOR
- those previously exposed

- 6.4 years [range, 2.1-18.5]) than non-BCMA-exposed patients
- Prior BCMA-exposed patients had a median of 6 prior lines (PL) of



Multiple Myeloma

